---- Eine Chinesische pharmaceutist verzichtet der Traditionellen Chinesischen Medizin bei einer TCM-Apotheke in der Stadt Xuchang, der Central China Provinz Henan, 7. November 2.
--FILE--A Chinese pharmaceutist dispenses traditional Chinese medicine at a TCM pharmacy in Xuchang city, central China's Henan province, 7 November 2013. Kanglaite Injection (KLT), a drug that contains anti-cancer substances extracted from coix seed, has recently been cleared by the US Food and Drug Administration (FDA) to undergo phase III clinical trials. KLT first underwent trials in 2001, making it the first traditional Chinese medicine (TCM) to go through the FDA approval process. During the second phase, the drug proved to prolong pancreatic, lung and liver patients' lives by 1.9 months when used with chemotherapy, exceeding the success rate of existing Western cancer treatments. On Saturday, Li Dapeng, the developer of the herbal remedy and a researcher at Zhejiang Chinese Medical University, announced that phase II was completed. "After promising results from the phase II clinical trials, they are permitting us to move on to the third and final phase, where a larger number of volunteer cancer patients will be involved, " Li was quoted as saying in anECNS report. "If everything goes smoothly, KLT will hit the U.S. market in three years."
